• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    9/7/23 9:06:05 AM ET
    $AGLE
    $ASXC
    $CBAY
    $CPHI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AGLE alert in real time by email

    Gainers

    • Asensus Surgical (AMEX:ASXC) shares rose 37.2% to $0.4 during Thursday's pre-market session. The company's market cap stands at $104.9 million.
    • China SXT Pharmaceuticals (NASDAQ:SXTC) stock increased by 20.58% to $0.14. The market value of their outstanding shares is at $1.9 million.
    • CymaBay Therapeutics (NASDAQ:CBAY) shares increased by 17.49% to $16.25. The company's market cap stands at $1.5 billion.
    • CervoMed (NASDAQ:CRVO) shares rose 17.47% to $5.31. The company's market cap stands at $7.2 million.
    • Mira Pharmaceuticals (NASDAQ:MIRA) stock increased by 16.46% to $6.79. The company's market cap stands at $100.1 million.
    • China Pharma Holding (AMEX:CPHI) shares moved upwards by 13.46% to $0.18. The market value of their outstanding shares is at $2.0 million.

    Losers

    • Palisade Bio (NASDAQ:PALI) stock fell 40.4% to $0.86 during Thursday's pre-market session. The company's market cap stands at $5.8 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares fell 29.42% to $1.68. The company's market cap stands at $5.2 million.
    • Aeglea BioTherapeutics (NASDAQ:AGLE) shares declined by 21.67% to $0.47. The company's market cap stands at $47.5 million.
    • Inspire Veterinary (NASDAQ:IVP) stock fell 17.16% to $2.27. The market value of their outstanding shares is at $27.1 million.
    • Heart Test Laboratories (NASDAQ:HSCS) stock declined by 15.18% to $0.67. The market value of their outstanding shares is at $6.9 million.
    • Trevena (NASDAQ:TRVN) stock declined by 11.5% to $0.89. The market value of their outstanding shares is at $12.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AGLE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGLE
    $ASXC
    $CBAY
    $CPHI

    CompanyDatePrice TargetRatingAnalyst
    Palisade Bio Inc.
    $PALI
    2/25/2026$5.00Buy
    Stifel
    Palisade Bio Inc.
    $PALI
    1/9/2026$7.00Buy
    B. Riley Securities
    Palisade Bio Inc.
    $PALI
    12/29/2025$25.00Overweight
    Piper Sandler
    CervoMed Inc.
    $CRVO
    12/18/2025Overweight
    Cantor Fitzgerald
    CervoMed Inc.
    $CRVO
    3/13/2025$14.00Neutral → Buy
    Chardan Capital Markets
    CervoMed Inc.
    $CRVO
    12/17/2024Buy → Neutral
    H.C. Wainwright
    CervoMed Inc.
    $CRVO
    12/11/2024Buy → Neutral
    Chardan Capital Markets
    CervoMed Inc.
    $CRVO
    12/11/2024Overweight → Underweight
    Morgan Stanley
    More analyst ratings

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Donald Allen bought $8,356 worth of shares (5,000 units at $1.67), increasing direct ownership by 87% to 10,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/21/26 4:05:24 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Williams Donald Allen bought $9,400 worth of shares (5,000 units at $1.88), increasing direct ownership by 687% to 5,728 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    1/13/26 9:43:07 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Commercial and Business Winton Matthew bought $41,430 worth of shares (5,000 units at $8.29), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

    4 - CervoMed Inc. (0001053691) (Issuer)

    11/19/25 7:46:15 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    SEC Filings

    View All

    CervoMed Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - CervoMed Inc. (0001053691) (Filer)

    2/18/26 4:25:18 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.

    SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

    2/17/26 4:39:49 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Palisade Bio Inc.

    SCHEDULE 13G/A - PALISADE BIO, INC. (0001357459) (Subject)

    2/17/26 4:00:03 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIVDELZI issued to CYMABAY THERAPEUTICS INC

    Submission status for CYMABAY THERAPEUTICS INC's drug LIVDELZI (ORIG-1) with active ingredient SELADELPAR has changed to 'Approval' on 08/14/2024. Application Category: NDA, Application Number: 217899, Application Classification: Type 1 - New Molecular Entity

    8/14/24 12:53:53 PM ET
    $CBAY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Aminov Erez was granted 125,000 shares, exercised 613,595 shares at a strike of $0.96 and sold $1,294,685 worth of shares (613,595 units at $2.11), increasing direct ownership by 4% to 3,592,666 units (SEC Form 5)

    5 - MIRA PHARMACEUTICALS, INC. (0001904286) (Issuer)

    2/17/26 8:30:02 PM ET
    $MIRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Jones Mitchell Lawrence converted options into 8,000 shares and sold $3,481 worth of shares (1,989 units at $1.75), increasing direct ownership by 83% to 13,263 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:10:12 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO, CFO Finley John David converted options into 13,333 shares and sold $6,818 worth of shares (3,896 units at $1.75), increasing direct ownership by 53% to 27,353 units (SEC Form 4)

    4 - PALISADE BIO, INC. (0001357459) (Issuer)

    2/13/26 8:07:40 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026

    Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiated, colon-targeted PDE4 approach Translational analyses confirm local suppression of TNF-α, JAK–STAT, NF-κB, MAPK and TGF-β signaling in colon tissue with minimal peripheral immune modulation Data presented at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, Sweden Carlsbad, CA, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmac

    2/23/26 8:40:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on Palisade Bio with a new price target

    Stifel initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $5.00

    2/25/26 7:53:12 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    B. Riley Securities initiated coverage on Palisade Bio with a new price target

    B. Riley Securities initiated coverage of Palisade Bio with a rating of Buy and set a new price target of $7.00

    1/9/26 9:07:04 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Piper Sandler initiated coverage on Palisade Bio with a new price target

    Piper Sandler initiated coverage of Palisade Bio with a rating of Overweight and set a new price target of $25.00

    12/29/25 7:10:24 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    Leadership Updates

    Live Leadership Updates

    View All

    Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board

    Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn's disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company advancing next-generation, once-daily oral PDE4 inhibitor prodrugs engineered for targeted delivery to the terminal ileum and colon, today announced the appointment of Bram Verstockt, MD, PhD, to its Clinical Advisory Board (CAB). Dr. Verstockt is an internationally recognized expert in inflammatory bowel disease (IBD) and a leader in precisi

    2/17/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

    Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's disease, and late-stage clinical trial design Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission planned for the first half of 2026 Carlsbad, CA, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today an

    1/29/26 8:45:00 AM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Trevena Inc.

    SC 13G/A - TREVENA INC (0001429560) (Subject)

    11/14/24 4:43:11 PM ET
    $TRVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Palisade Bio Inc.

    SC 13G - PALISADE BIO, INC. (0001357459) (Subject)

    11/14/24 3:35:13 PM ET
    $PALI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by CervoMed Inc.

    SC 13G - CervoMed Inc. (0001053691) (Subject)

    11/14/24 3:09:10 PM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGLE
    $ASXC
    $CBAY
    $CPHI
    Financials

    Live finance-specific insights

    View All

    HeartSciences Provides Business Update and Reports First Quarter of Fiscal 2026 Financial Results

    Southlake, TX, Sept. 11, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the first quarter of fiscal 2026 ended July 31, 2025 ("FQ1 2026") and provided a business update highlighting continued progress. First Quarter and Recent Highlights HeartSciences has made substantial progress during FQ1 2026 which saw the Company achieve an FDA Breakthrough Device Designation and successfully launched MyoVista Insights. MyoVista Insights™ Software Platform HeartScie

    9/11/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care

    CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

    Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP) Conference call and webcast today at 8:00 AM ET today to discuss results BOSTON, July 28, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc

    7/28/25 7:00:00 AM ET
    $CRVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results

    Southlake, TX, July 24, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (NASDAQ:HSCS, HSCSW)) ("HeartSciences" or the "Company"), an artificial intelligence ("AI")-powered medical technology company transforming ECGs/EKGs to enable earlier detection of heart disease, today announced its financial results for the fiscal year ended April 30, 2025, and provided a business update highlighting significant strategic progress. Fiscal 2025 and Business Highlights HeartSciences made substantial advancements during fiscal year 2025, marking a pivotal shift in its strategy to enhance the clinical value of ECGs through AI and cloud-based technologies that can be deployed across diverse healthcare settin

    7/24/25 4:15:00 PM ET
    $HSCS
    Industrial Specialties
    Health Care